# Phase 2 Study of VGT-309 in Lung Cancer

Source: https://onco.cc/trials/nct05400226/  
OnCo record `nct05400226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abenacianine run by Vergent Bioscience, Inc., completed.

## Summary

Phase 2 Study of VGT-309 in Lung Cancer is a phase 2 interventional study registered as NCT05400226 by Vergent Bioscience, Inc., with 40 participants enrolled, started 2022-05-24. Conditions recorded: Lung Cancer. Interventions recorded: VGT-309.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05400226
- Phase: 2
- Setting: A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Lung Cancer Surgery
- Sponsor: Vergent Bioscience, Inc.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05400226: https://clinicaltrials.gov/study/NCT05400226

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- drugs: [Abenacianine](https://onco.cc/drugs/abenacianine/)
- companies: [Vergent Bioscience](https://onco.cc/companies/vergent-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct05400226.json